(Reuters) – Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. There are few treatment …
Trending at Lumira Ventures
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing …
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
Phase 2b Trial Design and Enrolled Patient Demographics to be Presented at the 41st European Cystic Fibrosis Society Conference ATLANTA – May 17, 2018 – Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with …
Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines
New patents build on previously granted composition of matter protection for acebilustat, with additional intellectual protection for use in cystic fibrosis, as well as new compositions for second generation anti-inflammatory molecules Acebilustat, the most advanced new candidate in the CF …
Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
ATLANTA, GA – Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the successful completion of a Series E financing led by Invus. Additional investors in the financing include Domain …
Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial.
200 Patients Enrolled Exceeds Target, Top Line Results are Expected in Mid-2018 ATLANTA, GA–(May 17, 2017) – Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare pulmonary diseases, announced today the full enrollment …
Celtaxsys Welcomes New Board Member Abel De La Rosa
Atlanta, GA. – Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases, announced today the appointment of Dr. Abel De La Rosa to the company board of directors. He currently serves …
Celtaxsys Announces Publication of Clinical Trial Results in Patients with Cystic Fibrosis
ATLANTA, GA–(Marketwired – November 03, 2016) – Celtaxsys, Inc., a clinical stage drug development company advancing therapies for patients with rare inflammatory diseases, announced today the publication of the second paper detailing the results from Phase 1 clinical trials for …
Celtaxsys Announces Publication of Results Demonstrating the Safety, Tolerability and Optimal PK/PD Profile of First-In-Class Anti-Inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials Including Cystic Fibrosis Patients
ATLANTA, GA–(Marketwired – October 28, 2016) – Celtaxsys, Inc., a clinical stage drug development company focused on advancing therapies for patients with rare inflammatory diseases, announced today the publication of the first in a series of papers detailing the results …
Lumira Capital Portfolio Company Celtaxsys, Inc. Receives Georgia Bio 2016 Deal of the Year Award
January 22, 2016 Toronto, Canada – Lumira Capital portfolio company Celtaxsys, Inc. this week received the Georgia Bio 2016 Deal of the Year award for pharmaceutical, biotechnology, healthcare IT and medical device companies. The annual awards recognize the most …
Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
ATLANTA, Oct. 8, 2015 /PRNewswire/ — Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for …
Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF)
Forty-eight week trial to target lung inflammation, still the main cause of morbidity and mortality associated with CF ATLANTA, July 6, 2015 /PRNewswire/ — Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with …
Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne
Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, …
Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial
ATLANTA, June 2, 2015 /PRNewswire/ — Celtaxsys, a clinicalstage drug development company focused on advancing care for patients sufferingfrom inflammatory diseases, including those with rare and orphan inflammatorydiseases, announced today that it has received a development award for $5million from …